Management of Hypertension and Multiple Risk Factors to Enhance Cardiovascular Health
Launched by DUKE-NUS GRADUATE MEDICAL SCHOOL · Dec 31, 2014
Trial Information
Current as of May 02, 2025
Completed
Keywords
ClinConnect Summary
1. Background:
Cardiovascular diseases (CVD) are the leading cause of disability and death in Singapore, and consume substantial healthcare resources. Uncontrolled hypertension confers the highest attributable risk of CVD. About one in four adults suffer from hypertension in Singapore, 50% of them have uncontrolled blood pressure (BP), and management is especially sub-optimal among those with concomitant diabetes or dyslipidemia. Evidence suggests that well structured programs of care delivery are effective in lowering BP and preventing CVD. However, there is lack of empirical data on s...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 40 years or older
- • Singapore citizen and Permanent Resident
- • Individuals visiting the recruiting polyclinic at least twice during the last 1 year
- • Individuals with with previously diagnosed hypertension and uncontrolled blood pressure (Systolic BP 140 mmHg and above and diastolic BP 90 mmHg)
- Exclusion Criteria:
- • Individuals with active systemic illness including fever
- • Individuals with recent hospitalization (i.e. during last 4 months),
- • Individuals with clinically unstable heart failure (i.e. Ejection fraction \<20% or complaint of shortness of breath at rest)
- • Individuals with advanced kidney disease (i.e. estimated Chronic kidney disease (CKD) -Epi glomerular filtration rate \<40 ml/min/1.73m2 or nephrotic range proteinuria (i.e. 3g/d or more))
- • Individuals with known advanced liver disease (i.e. Child-Pugh Stage C)
- • Individuals with pregnancy
- • Individuals with any other major debilitating disease or
- • Individuals with mental illness that precludes validity of informed consent
About Duke Nus Graduate Medical School
Duke-NUS Graduate Medical School is a leading biomedical research institution located in Singapore, renowned for its commitment to advancing medical education, research, and healthcare innovation. As a partnership between Duke University in the United States and the National University of Singapore, the school emphasizes a collaborative approach to tackling pressing health challenges through cutting-edge clinical trials and interdisciplinary research. With a focus on translating scientific discoveries into practical applications, Duke-NUS plays a pivotal role in shaping the future of medicine and healthcare in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Singapore, , Singapore
Singapore, , Singapore
Patients applied
Trial Officials
Tazeen H Jafar, MD, MPH
Principal Investigator
Duke-NUS Graduate Medical School
Ngiap Chuan Tan, MBBS
Principal Investigator
SingHealth Polyclinics, Research
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials